Certolizumab Pegol biosimilar (Hetero Biopharma)

N/A

Report date: 2025/01/16 15:10:35

Base Information

Drug NameCertolizumab Pegol biosimilar (Hetero Biopharma)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHetero Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHetero Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A